Archon Capital Management LLC Buys New Shares in CryoPort, Inc. $CYRX

Archon Capital Management LLC bought a new position in shares of CryoPort, Inc. (NASDAQ:CYRX) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 172,807 shares of the company’s stock, valued at approximately $1,289,000. Archon Capital Management LLC owned approximately 0.34% of CryoPort as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CYRX. Kennedy Capital Management LLC acquired a new stake in shares of CryoPort during the 2nd quarter worth approximately $4,084,000. Acadian Asset Management LLC raised its stake in shares of CryoPort by 106.4% in the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company’s stock valued at $2,911,000 after purchasing an additional 247,288 shares in the last quarter. Norges Bank bought a new position in CryoPort in the second quarter worth $1,624,000. AQR Capital Management LLC boosted its stake in CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares in the last quarter. Finally, Philadelphia Trust Co. increased its holdings in CryoPort by 160.6% in the 2nd quarter. Philadelphia Trust Co. now owns 252,336 shares of the company’s stock valued at $1,882,000 after buying an additional 155,500 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of CryoPort in a research report on Monday, November 24th. Needham & Company LLC raised their price target on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. BTIG Research lifted their price objective on CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Finally, UBS Group upped their price objective on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.83.

Insider Activity

In other news, Director Robert J. Hariri sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the completion of the transaction, the director directly owned 51,275 shares in the company, valued at approximately $497,880.25. The trade was a 32.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.

CryoPort Stock Performance

Shares of CryoPort stock opened at $9.88 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $11.44. The firm has a market cap of $494.69 million, a P/E ratio of 8.44 and a beta of 1.51. The firm has a 50 day simple moving average of $9.39 and a 200 day simple moving average of $8.34.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. Sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.